Pharma Industry News 4 November 2025

AbbVie Stock (ABBV) Today: Skyrizi’s Canada Win, Dividend Hike and Big-Money Moves — November 28, 2025

AbbVie Inc. (NYSE: ABBV) ended Friday’s session almost unchanged, closing around $227.70 per share, up a negligible 0.02%, after earlier trading slightly in the red. StockAnalysis+2StockAnalysis+2 Even with today’s flat finish, the pharma giant remains one of 2025’s standout healthcare

28 November 2025

Novo Nordisk Stock Today, 28 November 2025: Goldman Sachs Trims Target as Obesity Pipeline Fights Back

Novo Nordisk (NYSE: NVO) shares are trying to stabilise after a bruising November as fresh obesity‑drug data, a higher‑dose Wegovy filing and new analyst calls collide with lingering worries about growth and competition. 1. How Novo Nordisk stock is trading

28 November 2025

Analyst Ratings · Investment News · NYSE:NVO · Obesity Treatments · Pharma Industry · Stock Market

Eli Lilly (LLY) Stock Outlook Before Market Open on November 28, 2025: Trillion‑Dollar Pharma in Focus

As U.S. markets prepare for a shortened Black Friday session on Friday, November 28, 2025, Eli Lilly and Company (NYSE: LLY) will open trading as one of the most closely watched stocks on Wall Street. The drugmaker has just joined

27 November 2025

Company Outlook · Financial News · Investment Analysis · NYSE:LLY · Pharma Industry · Stock Market

Eli Lilly (LLY) Stock on November 26, 2025: Trillion‑Dollar Milestone, Pricing Shake‑Up and Stock‑Split Buzz

Eli Lilly and Company (NYSE: LLY) is having another headline‑heavy session on Wednesday, November 26, 2025, as investors digest its new status as the first trillion‑dollar healthcare company, fresh moves on obesity‑drug pricing, and growing chatter about a potential stock

26 November 2025

Company Analysis · Financial Trends · Investment News · NYSE:LLY · Pharma Industry · Stock Market

Pfizer (PFE) Stock Today: Near‑7% Dividend Yield, Obesity Bet and Pipeline Shift Take Center Stage – November 25, 2025

As investors head into the Tuesday, November 25 session, Pfizer Inc. (NYSE: PFE) remains one of Wall Street’s most closely watched healthcare names. After a brutal comedown from its pandemic-era highs, the drugmaker is trying to convince the market that

25 November 2025

Dividends · Investment Strategies · Market Analysis · Pharma Industry · Stocks

Moderna (MRNA) Stock Today, November 23, 2025: Short-Seller Pressure, $1.5 Billion Loan and mRNA Pipeline Reset

Moderna Inc. (NASDAQ: MRNA) enters Sunday, November 23, 2025, as one of the most controversial and heavily shorted stocks in the S&P 500. The biotech is trading near its 52‑week low after the COVID‑vaccine boom faded, yet it’s rolling out

23 November 2025

Biotech News · Financial Updates · Investment Analysis · Pharma Industry · Stock Market

Metsera (MTSR) News Today, 21 November 2025: Pfizer’s $10 Billion Buyout, $6 Billion Bond Sale and What It Means for Investors

Pfizer has closed its up to $10 billion acquisition of Metsera (MTSR) and raised $6 billion in bonds to help fund the deal. Here’s what today’s developments mean for former Metsera shareholders, Pfizer investors and the future of the obesity

21 November 2025

Financial Analysis · Investment News · Mergers & Acquisitions · NASDAQ:MTSR · NYSE:PFE · Pharma Industry · Stock Market

LifeMD (LFMD) Slashes Wegovy and Ozempic Cash-Pay Price to $199 as Q3 2025 Earnings and GLP‑1 Price War Heat Up

LifeMD (NASDAQ: LFMD) announced the lowest nationwide cash-pay pricing for Wegovy and Ozempic at $199 per month for new patients, just hours before its rescheduled Q3 2025 earnings release. Here’s what it means for patients, investors, and the GLP‑1 weight-loss

17 November 2025

Business News · Drug Pricing · Healthcare · Pharma Industry · Stock Market

Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Pfizer (PFE) Stock Today — Nov 7, 2025: Metsera Bidding War Intensifies, Dividend Record Date, and What’s Moving the Share Price

Last updated: Nov 7, 2025 (19:23 UTC) Pfizer (NYSE: PFE) shares were trading around $24.28, down roughly 2.3% intraday, as investors weighed new twists in the Metsera takeover fight and marked today’s dividend record date. As of the latest print,

7 November 2025

Dividends · Investment Strategies · NYSE:NVO · NYSE:PFE · Pfizer News · Pharma Industry · Stock Market

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Stock Today (Nov 6, 2025): NVO steadies as White House GLP‑1 pricing deal lands; $10B Metsera bidding war heats up

Date: Thursday, November 6, 2025Ticker: NVO (NYSE) At a glance: price action and catalysts Novo Nordisk stock traded around $47.36 as of 17:52 UTC, after opening at $47.75 and moving between $46.91–$49.49 on heavy volume. The tape is being driven

6 November 2025

Healthcare Policy · Investment News · Novo Nordisk · NYSE:NVO · Pharma Industry · Stock Market

Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera Stock Overview and Recent Performance Metsera’s stock has been on a meteoric rise in recent weeks, capped by a 20% jump on November 4, 2025 alone reuters.com reuters.com. The share price is now hovering in the low $70s reuters.com,

4 November 2025

Company Analysis · Investment Insights · Mergers & Acquisitions · NASDAQ:MTSR · NYSE:NVO · NYSE:PFE · Pharma Industry · Stock Market News

Scienture Holdings (SCNX) Surges on Coverage Breakthrough – Can This Pharma Underdog Deliver?

Company Profile & Background Scienture Holdings, Inc. is a tiny specialty pharmaceutical company focused on developing and commercializing novel formulations that address unmet needs in healthcare globenewswire.com globenewswire.com. The company’s roots trace back to a 2024 merger with TRxADE Health,

4 November 2025

Company Analysis · Financial News · Investment Insights · Pharma Industry · Stock Market

Pharma Industry News 4 November 2025 - 28 November 2025